ReviewACR open rheumatology2025
JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases.
Review in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- JAK inhibitor therapy in CANDLE syndrome: a systematic review of clinical outcomes in 46 patients.European journal of pediatrics · 2026Pooled it
- "Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".Current opinion in rheumatology · 2026Review
- How Organ Manifestations Beyond the Bone May Guide Risk Stratification and Treatment Decisions in Chronic Nonbacterial Osteomyelitis.Paediatric drugs · 2026Review
- Case Report: Successful Treatment With Apremilast of SAPHO Syndrome and Refractory Pain.International journal of rheumatic diseases · 2026Article
- Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health science reports · 2026Review
- A combined score based on anterior chest wall CT attenuation to aid recognition of SAPHO syndrome: a training-validation study.Frontiers in medicine · 2026Article
- SAPHO syndrome and pustular skin diseases: shared inflammatory circuits, divergent tissue outcomes, and the limits of a spectrum model.Frontiers in immunology · 2026Review
- JAK Inhibitors for Treatment of Pyoderma Gangrenosum and Sweet Syndrome: A Systematic Review of Published Case Reports.Dermatology research and practice · 2026Review
- Case Report: Rapid improvement with upadacitinib in a case of paradoxical skin lesions associated with SAPHO syndrome.Frontiers in immunology · 2026Article
- Coexistence of SAPHO syndrome and IgG4-related disease with Upadacitinib.Clinical & translational immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSynovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for SAPHO syndrome are necessary. JAK inhibitors (JAK-I) are a group of small-molecule drugs with a wide range of effects on inflammatory and autoimmune pathways.
methodsA systematic search was conducted using medical subject headings terms or keywords related to JAK-I and SAPHO syndrome through PubMed/Medline, Scopus, Web of Science, and Embase until September 8, 2024. The inclusion criteria included a patient diagnosed with SAPHO syndrome who received at least one JAK-I. We excluded reviews and animal studies.
resultsOf 287 initially researched articles, we included 34 articles. These 34 articles represent 72 patients with a mean age of 39.36 years. Of these, 56 (78%) were female. All patients had bone or joint involvement, and 64 patients had skin involvement. Seventy patients (97.2%) had received at least one treatment before using JAK-I. All patients received just one JAK-I. Of these, 54 (75%) received tofacitinib, 15 (20.8%) received baricitinib, and 3 (4.2%) received upadacitinib. All patients except one (98.6%) showed good to complete response. Ten patients (13.9%) showed a clinical adverse effect. All were taking tofacitinib, with adverse effects leading to drug discontinuation in just one of these patients.
conclusionJAK-I seems to be a promising treatment of SAPHO syndrome, with manageable adverse effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.